A retrospective, observational study of association between pretreatment inflammation-based factors and outcomes in patients with macular edema (ME) secondary to retinal vein occlusion (RVO) and its subtypes after intravitreal ranibizumab or conbercept implant
Latest Information Update: 20 Sep 2021
At a glance
- Drugs Conbercept (Primary) ; Ranibizumab (Primary)
- Indications Retinal oedema
- Focus Pharmacokinetics; Therapeutic Use
- 20 Sep 2021 New trial record